Friday, March 27, 2026 For Patients CME Credits Newsletters
Subscribe
You're in HCP Mode — summaries include clinical detail, dosing, trial data, and statistical outcomes.
You're in Patient Mode — summaries use plain language, avoiding clinical jargon.
Drug Pipeline PHASE3 ● Phase III

Phase 3 Trial Evaluates Safety and Immunogenicity of CHIKV VLP Vaccine in Children

Summary

A Phase 3 trial is assessing the safety and immunogenicity of the CHIKV VLP vaccine in children aged 1 to <12 years. Primary endpoints include the incidence of AESI, MAAEs, and SAEs, and the seroresponse rate on Day 22 in seronegative children.

Researchers are studying a new vaccine for chikungunya virus in children. They want to see if it is safe and helps the body build protection against the virus.

Monitor for updates on CHIKV VLP vaccine's safety and immunogenicity in children.
ClinicalTrials.gov · Published Mar 27, 2026
Full analysis →
CT.gov Drug Pipeline
Phase3
n=720
Mar 2026
Latest Research View all →
Pulmonology & Critical Care Phase II
Phase 2 Study: L-SABR Plus Standard Therapy in Metastatic NSCLC Patients
This Phase 2 trial evaluates the addition of liver stereotactic ablative radiotherapy (L-SABR) to standard drug therapy in metastatic NSCLC.…
Researchers are studying if adding a special type of radiation therapy helps patients with advanced lung cancer live longer without their di…
CT.gov 8h ago
Pulmonology & Critical Care Phase II
Ivonescimab Phase II Study Targets 55% DCR in Relapsed Pleural Mesothelioma
A Phase II trial evaluates ivonescimab in 38 pleural mesothelioma patients post-immunotherapy/chemotherapy. The study aims for a ≥55% diseas…
Researchers are testing a new drug called ivonescimab for patients whose pleural mesothelioma has come back after other treatments. The stud…
CT.gov 8h ago
Nephrology Phase II
Phase 2 Study Evaluates Frexalimab, Brivekimig, Rilzabrutinib in FSGS and MCD
A Phase 2a trial is assessing frexalimab, brivekimig, and rilzabrutinib for reducing proteinuria in FSGS and MCD. Primary outcome is the per…
Researchers are studying three new drugs to see how well they reduce protein in urine for patients with certain kidney diseases. The study a…
CT.gov 8h ago
Nephrology Phase II
Phase 2 Study: ManNAc for FSGS Shows Promise in Reducing Proteinuria
A Phase 2 trial is evaluating ManNAc for primary FSGS in 30 patients. Primary endpoints include proteinuria reduction and safety. Results pe…
Researchers are testing a new drug called ManNAc for people with a kidney disease that causes protein loss. The study aims to see if this dr…
CT.gov 8h ago
Rheumatology Phase III
Phase 3 Trial: Anifrolumab Shows Promise in SLE with BICLA Response as Primary Outcome
In a Phase 3 trial with 367 SLE patients, subcutaneous anifrolumab was tested against placebo. The primary endpoint is the BICLA response, b…
Researchers tested a new drug called anifrolumab for patients with lupus who were not improving on standard treatments. The study aimed to s…
CT.gov 8h ago
Rheumatology Phase III
Phase 3 Trial of Cenerimod for Lupus Nephritis: Efficacy and Safety Evaluation
A Phase 3 trial is assessing cenerimod's efficacy and safety in treating active lupus nephritis. The primary endpoint is complete renal resp…
This study is looking at a new drug called cenerimod to see if it helps improve kidney function in people with lupus nephritis. Researchers …
CT.gov 8h ago
Infectious Disease Phase II
Phase 2 Trial Evaluates mRNA Influenza Vaccines' Safety and Immunogenicity in Adults
This Phase 2 trial investigates the safety and immunogenicity of five mRNA-based influenza vaccines in 770 healthy adults. Primary outcomes …
This study is testing new flu vaccines made with mRNA technology in healthy adults. Researchers want to see how safe these vaccines are and …
CT.gov 8h ago
Infectious Disease Phase II
Dasatinib and Quercetin Show Promise in Improving Gait Speed in HIV-Associated Frailty
Phase II trial of dasatinib and quercetin (D+Q) in 82 HIV+ frail/prefrail adults shows potential in improving gait speed. Primary endpoint: …
Researchers are studying a combination of two drugs to see if they can help older adults with HIV who are frail. The treatment aims to impro…
CT.gov 8h ago
Infectious Disease RCT
Antibiotics for Appendicitis: 37.8% Recurrence, 44.3% Appendectomy at 10 Years
In a 10-year follow-up of the APPAC trial, 37.8% of patients treated with antibiotics for uncomplicated appendicitis experienced recurrence,…
This study looked at patients with uncomplicated appendicitis treated with antibiotics over ten years. It found that many patients had a ret…
JAMA 8h ago
More From This Week See all →
01
Rapid Diagnostics Align 65% of ICU Antibiotic Prescriptions with Pathogen Results
Infectious Disease · 8h ago RCT
02
Oral Sucrose Fails to Reduce Pain in Preterm Infants During Lung Ultrasound
Pediatrics · 8h ago RCT
03
Ondansetron Slightly Prolongs QTc Interval in Pediatrics Without Dysrhythmia Risk
Pediatrics · 8h ago Meta-analysis
04
Predictors of Saccadic Reaction Time in Zambian Children: Birth Spacing, Nutrition, and Diarrhea Impact
Pediatrics · 8h ago RCT
05
RAD51-foci Score Predicts Olaparib Efficacy in Advanced HER2-negative Breast Cancer
OB/GYN & Women's Health CT.gov · 8h ago Phase II
CT.gov · Phase 3 Trial Evaluates Safety and Immunogenicity of CHIKV VLP Vaccine in Childr… CT.gov · Phase 2 Study: L-SABR Plus Standard Therapy in Metastatic NSCLC Patients CT.gov · Ivonescimab Phase II Study Targets 55% DCR in Relapsed Pleural Mesothelioma CT.gov · Phase 2 Study Evaluates Frexalimab, Brivekimig, Rilzabrutinib in FSGS and MCD CT.gov · Phase 2 Study: ManNAc for FSGS Shows Promise in Reducing Proteinuria CT.gov · Phase 3 Trial: Anifrolumab Shows Promise in SLE with BICLA Response as Primary O…